Company Overview and News

3
Global Hemp Group Provides Update on Successful Launch of Cash Crop Today Investor & Business Resource Summit

2018-06-14 globenewswire
VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) is pleased to announce that the Company’s 50% owned subsidiary Cash Crop Today Media, LLC hosted its first Investor and Business Resource Summit this past weekend in Beverly Hills, California.
GBHPF GHG

5
Marijuana Company of America and Global Hemp Group Provide Update on New Brunswick Hemp Project

2018-05-22 globenewswire
ESCONDIDO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, is pleased to provide an update on its New Brunswick Hemp Project with joint venture partner, Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) (the “Partners”).
GBHPF GHG MCOA

5
Global Hemp Group and Marijuana Company of America Provide an Update on Operations for Their Joint Venture CBD Hemp Farm in Scio, Oregon

2018-05-15 globenewswire
VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) and joint venture partner Marijuana Company of America, Inc. (OTC:MCOA) (the “Partners”) are pleased to provide an update on their CBD hemp farming project in Scio, Oregon (the “Project”).
GBHPF GHG MCOA

5
Global Hemp Group and Marijuana Company of America Form Joint Venture to Cultivate High Yielding CBD Hemp in Scio, Oregon

2018-05-09 globenewswire
VANCOUVER, B.C., May 09, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) is pleased to announce that is has signed a Joint Venture Agreement (the “Agreement”) with MARIJUANA COMPANY OF AMERICA, INC. (OTC:MCOA) to cultivate high yielding CBD hemp at its recently acquired 109 acre farm (see news release of May 1, 2018) in Scio, Oregon (the “Project”).
GBHPF GHG MCOA

5
Marijuana Company of America and Global Hemp Group Form Joint Venture to Cultivate High Yielding CBD Hemp in Scio, Oregon

2018-05-09 globenewswire
ESCONDIDO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – MARIJUANA COMPANY OF AMERICA, INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, is pleased to announce that it has signed a Joint Venture Agreement (the “Agreement”) with GLOBAL HEMP GROUP INC. (“GHG”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) to cultivate legal high yielding CBD from industrial hemp at its recently acquired 109 acre farm (see news release of May 1, 2018) in Scio, Oregon.
GBHPF GHG MCOA

5
Marijuana Company of America and Global Hemp Group Announce Acquisition of 109 Acres of Prime Agricultural Property for Hemp CBD Production in Oregon

2018-05-01 globenewswire
ESCONDIDO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – MARIJUANA COMPANY OF AMERICA, INC. (“MCOA” or the “Company”) (OTC:MCOA) is pleased to announce that the Company, in partnership with Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) has acquired a 109-acre agricultural property in Scio, Oregon (the “Property”) for the cultivation of high CBD yielding hemp for the upcoming 2018 growing season.
GBHPF GHG MCOA

5
Global Hemp Group and Marijuana Company of America Announce Acquisition of 109 Acres of Prime Agricultural Property for Hemp CBD Production in the State of Oregon

2018-05-01 globenewswire
VANCOUVER, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) is pleased to announce that the Company, in partnership with Marijuana Company of America, Inc. (OTC:MCOA) has acquired a 109 acre agricultural property in Scio, Oregon (the “Property”) for the cultivation of high CBD yielding hemp for the upcoming 2018 growing season.
GBHPF GHG MCOA

6
Cannabis Science, Inc. Announces Support for the Global Hemp Group and Senator Mitch Mcconnell's Hemp Legislation; CBIS Ceo Eyes 4/20 for a CBIS Pharmacy Grand Opening Party

2018-03-27 globenewswire
IRVINE, CA , March 27, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it fully supports the Global Hemp Group and the Hemp Farming Act of 2018.
GBHPF CBIS GHG

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to CNSX:GHG / Global Hemp Group Inc on message board site Silicon Investor.

DGHG